Clinical Research in Cardiology最新文献

{"title":"Absorb® bioresorbable scaffold in \"established\" versus \"off-label\" coronary lesions: 5-year data from the GABI-R® registry.","authors":"Aydin Huseynov, Michael Behnes, Holger Nef, Thomas Riemer, Steffen Schneider, Thomas Pfannebecker, Stephan Achenbach, Julinda Mehilli, Thomas Münzel, Tommaso Gori, Jochen Wöhrle, Ralf Zahn, Johannes Kastner, Axel Schmermund, Gert Richardt, Christian W Hamm, Ibrahim Akin","doi":"10.1007/s00392-025-02707-3","DOIUrl":"10.1007/s00392-025-02707-3","url":null,"abstract":"<p><strong>Background: </strong>The potential benefits of bioabsorbable stents can be better assessed over the long term. The implantation of bioresorbable scaffold (BRS) in situations with off-label indications provides real-world insights into how clinical events differ in contrast to standard proved indications.</p><p><strong>Objectives: </strong>The study provides long-term follow-up data about the use of bioresorbable scaffold (BRS) for off-label compared with approved indications.</p><p><strong>Methods: </strong>Five-year outcome data of an everolimus-eluting, poly-L-lactic acid-based bioresorbable scaffold system (ABSORB, Abbott Vascular, Santa Clara, CA, USA) were evaluated in the prospective, non-interventional, multicenter real-world German-Austrian ABSORB-RegIstRy (GABI-R). The patients were enrolled from a total of 93 centers. Data processing and prospective follow-up were conducted centrally and independently of industry.</p><p><strong>Results: </strong>A total of 3082 patients were enrolled between 2013 and 2016. Most patients were included into the off-label group (2317, 75.2%). ST-elevation myocardial infarction (STEMI) was significantly more common in the off-label group (35.9% vs. 27.8%, p = 0.003), and the extent of coronary heart disease was higher in the off-label group (coronary 3 vessel disease 28.4% vs. 22.4%, p < 0.001). Patients with off-label indications had statistically significant higher rates of stent thrombosis after 30 days (1.08% vs. 0.26%, p = 0.04) and target vessel failure (TVF) after 6 months (4.62% vs. 2.61%, p = 0.02).</p><p><strong>Conclusions: </strong>The off-label use of BRS is associated with a higher rate of stent thrombosis in the short term and in the long term with higher MACE events considering more complex lesions and a higher morbidity. In the long term, there are no differences regarding stent thrombosis.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1084-1094"},"PeriodicalIF":3.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease.","authors":"Liang-Yu Lin, Ting-Ting Chang, Hsin-Bang Leu, Chin-Chou Huang, Tao-Cheng Wu, Ruey-Hsin Chou, Po-Hsun Huang, Wei-Hsian Yin, Wei-Kung Tseng, Yen-Wen Wu, Tsung-Hsien Lin, Hung-I Yeh, Kuan-Cheng Chang, Ji-Hung Wang, Chau-Chung Wu, Jaw-Wen Chen","doi":"10.1007/s00392-024-02458-7","DOIUrl":"10.1007/s00392-024-02458-7","url":null,"abstract":"<p><strong>Background: </strong>Both the clinical and mechanistic impacts of endocan were not well elucidated especially in coronary artery disease (CAD).</p><p><strong>Objective: </strong>This study aimed to investigate the prognostic and potential pathological role of endocan for cardiovascular (CV) events in stable CAD patients.</p><p><strong>Methods: </strong>A total of 1,071 stable CAD patients with previous percutaneous coronary intervention (PCI) were enrolled prospectively in a nationwide Biosignature study. Another cohort of 76 CAD patients with or without PCI were enrolled for validation. Baseline biomarkers including endocan level was measured and total CV events especially hard CV events (including CV mortality, non-fatal myocardial infection and stroke) during follow-up were identified. Circulating endothelial progenitor cells (EPCs) as an in vivo biological contributor to vascular repairment from CAD patients were used for the in vitro functional study.</p><p><strong>Results: </strong>After 24 months, there were 42 patients (3.92%) with hard CV events and 207 (19.3%) with total CV events in the study group. The incidence of both events was increased with the tertiles of baseline endocan level (hard events: 1.7%,3.4%, and 6.7% in 1st,2nd, and 3rd tertile respectively, p = 0.002; total events: 13.8%vs.16.2%vs.28.0%, p < 0.0001). Multivariate regression analysis revealed the independent association of endocan level with total and hard CV events. These findings were validated in another cohort with a 5-year follow-up. Furthermore, in vitro inhibition of endocan improved cell migration and tube formation capacities, and reduced cell adhesiveness of EPCs from CAD patients.</p><p><strong>Conclusions: </strong>Endocan might be a novel prognostic indicator, mechanistic mediator, and potential therapeutic target for clinical CAD.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"952-968"},"PeriodicalIF":3.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140915917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative flow ratio of the donor coronary artery supplying a chronic total occlusion territory.","authors":"Karim Elbasha, Sultan Alotaibi, Mohamed Samy, Nader Mankerious, Ralph Toelg, Volker Geist, Gert Richardt, Abdelhakim Allali","doi":"10.1007/s00392-024-02589-x","DOIUrl":"10.1007/s00392-024-02589-x","url":null,"abstract":"<p><strong>Background: </strong>Coronary physiology to guide multi-vessel coronary intervention is associated with better outcome. In the presence of a coronary chronic total occlusion (CTO), hemodynamic evaluation of intermediate lesions in the donor coronary artery supplying a CTO territory still has limitations. We aim to evaluate implementing quantitative flow ratio (QFR) in assessing angiographically intermediate lesions of the main donor coronary artery supplying a CTO territory.</p><p><strong>Methods: </strong>We recruited 219 patients with a single main donor vessel to a CTO territory from a single-center CTO registry between 2017 and 2020. Angiographically intermediate coronary lesions of the donor vessels were evaluated using offline QFR before and at a median of 6 months after successful percutaneous coronary intervention (PCI) of CTO.</p><p><strong>Results: </strong>The mean age of the study population was 66.9 ± 11.3 years, and 77.6% were males. Three-vessel disease was documented in 49.8%. The mean QFR value increased significantly in the donor vessels after successful CTO revascularization (0.93 ± 0.062 vs. 0.95 ± 0.046, p < 0.001) and was more prominent in donor vessels with angiographically intermediate stenosis (0.88 ± 0.063 vs. 0.92 ± 0.053, p < 0.001). While the change in QFR was not significant in angiographically normal donor vessel (0.97 ± 0.025 vs. 0.97 ± 0.026, p = 0.814). Fifteen patients had hemodynamically significant stenosis in the donor coronary artery (QFR ≤ 0.80) before CTO-PCI. Among those patients, 40% (n = 6) were turned to be non-significant with QFR > 0.80 after CTO recanalization, and 30% (n = 5) patients remained significant and were treated with PCI.</p><p><strong>Conclusion: </strong>QFR overestimates the severity of intermediate coronary lesions of a donor vessel supplying a CTO territory like other invasive modalities for physiology assessment.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1041-1048"},"PeriodicalIF":3.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of E- and A-wave adjacency after atrial fibrillation ablation.","authors":"Jumpei Saito, Kato Daiki, Sato Hirotoshi, Toshihiko Matsuda, Yui Koyanagi, Katsuya Yoshihiro, Yuma Gibo, Ishigaki Shigehiro, Soichiro Usumoto, Taro Kimura, Suguru Shimazu, Wataru Igawa, Seitaro Ebara, Toshitaka Okabe, Naoei Isomura, Masahiko Ochiai","doi":"10.1007/s00392-025-02714-4","DOIUrl":"https://doi.org/10.1007/s00392-025-02714-4","url":null,"abstract":"<p><strong>Background: </strong>In adult patients with systolic heart failure, the presence of adjacent, nonoverlapping E and A waves on Doppler echocardiography is associated with optimal cardiac output and favorable clinical outcomes. However, the clinical significance of echocardiographic adjacency in patients with atrial fibrillation (AF) remains uncertain. We aimed to explore the relationship between E- and A-wave adjacency assessed the day after catheter ablation and the recurrence of atrial arrhythmias (AR) following AF ablation.</p><p><strong>Methods: </strong>This study included patients with AF who underwent first-time arrhythmia ablation. Transthoracic echocardiography was performed on the day following catheter ablation to evaluate the presence of E- and A-wave adjacency. The relationship between overlap length and recurrence of AR after AF ablation was analyzed.</p><p><strong>Results: </strong>The study included 175 patients (124 males; mean age: 68 [range 52-79] years; mean CHA2DS2-Vasc score: 2 [range 0-4]; and 93 with paroxysmal AF) who underwent AF ablation. There were no significant differences between the two groups in terms of heart failure history or echocardiographic parameters prior to catheter ablation. However, the absolute overlap length was significantly prolonged in the AR group (59 [range 9-160] msec vs. 120 [range 28.6-226] msec; P < .001). Furthermore, the AR rate was significantly lower in the group without prolonged overlap length (hazard ratio, 0.15 [95% confidence interval, 0.07-0.30]; P < .001). These findings were consistent across all AF types.</p><p><strong>Conclusions: </strong>The length of E- and A-wave adjacency appears to be a significant predictor of AR following AF ablation.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted proteomic profiling of transcatheter edge-to-edge repair failure in patients with mitral regurgitation and heart failure.","authors":"Mattia Di Pasquale, Susana Ravassa, Matteo Pagnesi, Edoardo Pancaldi, Begoña López, Gorka San José, Cristina Gussago, Letizia Fiorentino, Alice Ravera, Lisa Serafini, Giuliano Chizzola, Carlo Mario Lombardi, Marco Metra, Arantxa González, Marianna Adamo","doi":"10.1007/s00392-025-02712-6","DOIUrl":"https://doi.org/10.1007/s00392-025-02712-6","url":null,"abstract":"<p><strong>Aims: </strong>To assess the changes in circulating biomarkers concentrations after mitral valve transcatheter edge-to-edge repair (M-TEER) and their relationship with procedural success vs. failure in patients with severe mitral regurgitation (MR) and heart failure (HF).</p><p><strong>Methods and results: </strong>Pre-procedural, post-intervention, and 30 days post-intervention plasma samples were analyzed for 266 different proteins using the Olink Proseek® Multiplex cardiovascular (CVD) II, CVD III, and inflammation panels, in patients with MR undergoing M-TEER. Multiple biomarkers showed a differential expression 30 days after M-TEER in patients with procedural failure vs. those with a successful evolution. The proteins upregulated in patients with procedural failure were functionally enriched in pathways related to immune regulation, inflammation, extracellular matrix organization, and cellular structures. After adjustment for confounding variables, increases in IL2RA, RAGE, IGFBP2, and COL1A1 values at 30 days post-intervention were associated with procedural failure. Changes in IGFBP2 and IL2RA values were also independently associated with pulmonary artery systolic pressure (PASP) increases after M-TEER.</p><p><strong>Conclusion: </strong>In a cohort of patients with severe MR undergoing M-TEER, differences in circulating biomarkers concentrations related to inflammation and fibrosis were observed between patients with procedural success as compared to those with procedural failure. Biomarkers known to be associated with HF severity were over-expressed in patients with procedural failure, compared with those with procedural success, after M-TEER.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of the 2019 guideline update on lipid-lowering therapy in patients with acute coronary syndromes.","authors":"Lukas Galli, Johannes Bernhard, Lore Schrutka, Patrick Haider, Klaus Distelmaier, Christian Hengstenberg, Konstantin A Krychtiuk, Walter S Speidl","doi":"10.1007/s00392-025-02716-2","DOIUrl":"https://doi.org/10.1007/s00392-025-02716-2","url":null,"abstract":"<p><strong>Background: </strong>The European Society of Cardiology regularly updates its clinical practice guidelines. However, it is not well established whether guideline changes have significant effects on actual clinical practice. Therefore, we retrospectively analyzed lipid-lowering therapy at discharge after acute coronary syndrome (ACS) in a 1-year period before and a 1-year period after publication of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, respectively.</p><p><strong>Methods and results: </strong>In total, we included 691 patients who were discharged alive after AMI. A total of 354 patients were treated in the period before, and 337 after the guideline change. After the guideline change, the proportion of patients discharged on high-dose statin was higher (89.3% vs 80.5%; p = 0.001) and ezetimibe was prescribed more often (31.2% vs 5.9%; p < 0.00001) resulting in more patients being discharged on high-intensity treatment (92.9% vs. 81.6%; p < 0.0001). Median on-treatment LDL-cholesterol was significantly higher in the period before (65 [IQR 47 to 90] mg/dL) than after the publication of the 2019 guidelines (48 [IQR 35 to 69] mg/dL; p < 0.0001). The LDL-C goal of < 55 mg/dL would have been reached by 37.5% patients in the earlier period and was reached by 62.9% in the later period (p < 0.0001).</p><p><strong>Conclusions: </strong>The update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias was associated with a significant improvement in the prescription of high-dose statin and ezetimibe in patients after ACS. The change of the guidelines rapidly translated into clinical practice resulting in improved risk factor control in patients at very high risk.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appointment as Editor-in-Chief of Clinical Research in Cardiology-goals and vision.","authors":"Ulrich Laufs","doi":"10.1007/s00392-025-02721-5","DOIUrl":"https://doi.org/10.1007/s00392-025-02721-5","url":null,"abstract":"","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of body mass index in acute myocardial infarction complicated by cardiogenic Shock: an ECLS-SHOCK subanalysis.","authors":"Tobias Schupp, Holger Thiele, Tienush Rassaf, Amir Abbas Mahabadi, Ralf Lehmann, Ingo Eitel, Carsten Skurk, Peter Clemmensen, Marcus Hennersdorf, Ingo Voigt, Axel Linke, Eike Tigges, Peter Nordbeck, Christian Jung, Philipp Lauten, Hans-Josef Feistritzer, Maria Buske, Janine Pöss, Taoufik Ouarrak, Steffen Schneider, Michael Behnes, Daniel Duerschmied, Steffen Desch, Anne Freund, Uwe Zeymer, Ibrahim Akin","doi":"10.1007/s00392-025-02717-1","DOIUrl":"https://doi.org/10.1007/s00392-025-02717-1","url":null,"abstract":"<p><strong>Background: </strong>The prognostic impact of overweight and obesity in patients with cardiogenic shock (CS) following acute myocardial infarction (AMI) is still a matter of debate. The present subanalysis of the ECLS-SHOCK trial sought to investigate the association between body mass index (BMI) and outcomes in patients with AMI-CS.</p><p><strong>Methods: </strong>Patients with AMI-CS enrolled in the multicenter, randomized ECLS-SHOCK trial between 2019 and 2022 were included. The prognostic impact of BMI was investigated stratified by BMI 18.5-24.9 kg/m², 25.0-29.9 kg/m² and ≥ 30.0 kg/m² with regard to the primary endpoint 30-day all-cause mortality.</p><p><strong>Results: </strong>Overall, 407 patients with AMI-CS were included with a median BMI of 27.7 kg/m² (interquartile range 24.8-30.8 kg/m²). Patients with a BMI ≥ 30.0 kg/m² (n = 115) were less likely males, had a higher burden of cardiovascular risk factors and higher rates of TIMI flow 0 before revascularization than patients with lower BMI values. The primary endpoint of all-cause mortality at 30 days occurred in 53.9%, 45.3% and 47.7% of patients with BMI ≥ 30.0 kg/m², 25.0-29.9 kg/m² and 18.5-24.9 kg/m², respectively. Using patients with a BMI 18.5-24.9 kg/m² as a reference, neither a BMI ≥ 30.0 kg/m² (OR = 1.28; 95% CI 0.76-2.16; p = 0.35) nor a BMI of 25.0-29.9 kg/m² (OR = 0.91; 95% CI 0.56-1.46; p = 0.68) were associated with an increased risk of all-cause mortality. Similar results were obtained regardless of allocation to extracorporeal life support (ECLS) or medical treatment only for all BMI groups. Safety endpoints did not differ across the different BMI groups.</p><p><strong>Conclusion: </strong>In this well-defined cohort of patients with AMI-CS, BMI was not associated with the risk of all-cause mortality, nor were we able to identify BMI subgroups who derived more benefit or less harm from ECLS therapy.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonists in dialysis patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis.","authors":"Tian Li, Tong Li, Yujun Xu, Diona Gjermeni, Lukas Heger, Dirk Westermann, Christoph B Olivier","doi":"10.1007/s00392-025-02711-7","DOIUrl":"https://doi.org/10.1007/s00392-025-02711-7","url":null,"abstract":"<p><strong>Aims: </strong>For patients with atrial fibrillation (AF) and preserved renal function, direct oral anticoagulants (DOACs) are superior to vitamin K antagonists (VKAs) for stroke prevention. However, the evidence in patients with end-stage kidney disease (ESKD) on dialysis remains inconclusive. In this systematic review and meta-analysis, we aim to compare the efficacy and safety of DOACs and VKAs in dialysis patients with nonvalvular AF.</p><p><strong>Methods and results: </strong>We conducted a systematic literature review of publications comparing DOACs and VKAs in dialysis patients with nonvalvular AF. Data of RCTs and cohort studies were synthesized separately. Outcomes were reported as risk ratios with 95% confidence intervals. Heterogeneity was assessed using I² statistics. Ten studies were included in this meta-analysis: 4 RCTs (DOACs, 269 patients; VKAs, 217) and 6 cohort studies (DOACs, 7039 patients; VKAs, 22,983). In RCTs, the risk for major bleeding was significantly lower with DOACs compared with VKAs (RR 0.64, 95% CI 0.42-0.99, I² = 0%). In cohort studies, DOAC was associated with a lower risk for all-cause death compared with VKAs; however, with high heterogeneity (RR 0.78, 95% CI 0.62-0.98, I² = 80%). No significant differences were found regarding ischemic stroke or systemic embolism and gastrointestinal bleeding.</p><p><strong>Conclusion: </strong>In dialysis patients with nonvalvular AF, DOACs were associated with significantly reduced risk for major bleeding in RCTs and significantly reduced risk for all-cause death in cohort studies. These findings suggest that DOACs may provide a higher net clinical benefit compared with VKAs in dialysis patients.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tribute to Professor Michael Böhm-architect of Clinical Research in Cardiology.","authors":"Norbert Frey","doi":"10.1007/s00392-025-02720-6","DOIUrl":"https://doi.org/10.1007/s00392-025-02720-6","url":null,"abstract":"","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}